{"id":"W4286295274","doi":"10.1200/jco.2022.40.16_suppl.5050","title":"Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; Abiraterone; Abiraterone acetate; Placebo; Internal medicine; Pharmacokinetics; Urology; Oncology; Pharmacology; Cancer; Androgen deprivation therapy; Androgen receptor; Chemistry; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001539657,0.0007930048,0.001091146,0.0003870399,0.0002283181,0.0006893661,0.0005451745,0.0004897079,0.003471926],"category_scores_gemma":[0.001667746,0.0003348632,0.0009359978,0.000508525,0.000463939,0.0005271786,0.0003265743,0.001459033,0.0004948527],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006607698,"about_ca_system_score_gemma":0.001258627,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007123476,"about_ca_topic_score_gemma":0.002128503,"domain_scores_codex":[0.9994946,0.0003091251,0.00002884441,0.00004835447,0.00006555069,0.00005360873],"domain_scores_gemma":[0.9988594,0.0003173908,0.0002890245,0.00007572067,0.00006687898,0.0003915827],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8666385,0.009110077,0.009949849,0.001249787,0.002331639,0.0002947069,0.0001702572,0.002294858,0.01387639,0.0001656991,0.003487129,0.09043121],"study_design_scores_gemma":[0.7834067,0.1794375,0.02608142,0.0001236155,0.001556563,0.0006731874,0.0000661167,0.001275615,0.002385916,0.0003261424,0.004627314,0.00004000196],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836994,0.009776991,0.0005072836,0.0005134417,0.00008040213,0.0009713176,0.00228076,0.00007645431,0.002093921],"genre_scores_gemma":[0.9879372,0.003375662,0.001132424,0.0005915686,0.000161978,0.0008431721,0.004382581,0.00002174552,0.001553783],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003471926,"threshold_uncertainty_score":0.0116148,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3205997998601303,"score_gpt":0.5146648703228783,"score_spread":0.194065070462748,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}